Antibody About Turn
A promising candidate is on the verge of entering clinical development… What happens when you see an opportunity to make it even better? Do you delay – or stick with it in the hope that it’s “good enough”?
Sam Cobb |
The introduction of antibody therapeutics has been one of the greatest, recent advances in drug development. These are often thought of as the large molecular weight monoclonal antibodies, but there are many other interesting antibody formats too with significant potential for human medicine. I am the founding CEO of AdAlta, a company that was launched with a focus on both shark antibodies and a human equivalent called the i-body. Both the shark antibody and the i-body have unique characteristics that support their inclusion in this next generation of antibody therapeutics.
A traditional mAb possesses both a heavy and light chain, but shark antibodies have only a heavy chain (similar to camel antibodies, which are attracting a great deal of attention in the research community). Both shark and camel antibodies have a very long CDR3 binding loop. The traditional binding loop in a human antibody is 8-10 amino acids, but in the shark it can consist of up to 30 residues, increasing binding affinity. Shark proteins are also very stable, you can boil them or put them in acid! We have even put the i-body and shark antibodies in proteases and found that they did not degrade.
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!